Keefer David R 4

What Happened David R. Keefer, a director of Dogwood Therapeutics, was granted 16,800 shares classified as a derivative acquisition on 2026-06-16. The award is reported at $0.00 per share (no cash paid at grant), so the reported cash consideration is $0.00. This transaction is an equity award (transaction code A) — a compensation/award grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-16; Filing date: 2026-06-17 (filed the next day; appears timely).
• Transaction type/code: A = Award/Grant; reported as a derivative acquisition.
• Price reported: $0.00 per share; total cash paid: $0.00.
• Shares acquired: 16,800 derivative shares.
• Shares owned after transaction: Not specified in the provided excerpt — see the full Form 4 for total holdings and any post-transaction ownership figures.
• Footnotes/conditions: None provided in the excerpt. The filing does not state vesting, tax withholding, or whether the award converts to common shares immediately.

Context This report reflects a stock-based compensation award to a director, which is common and differs from open-market buying or selling. Because the grant is reported as a derivative acquisition (typical for RSUs or similar awards), it may be subject to vesting and other conditions not shown in the excerpt. Such awards are compensation-related and should be interpreted differently than purchases or sales when assessing insider sentiment. For full details (vesting schedule, total holdings, and any conditions), consult the complete Form 4 filing.